Your browser doesn't support javascript.
loading
Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.
Hailemichael, Yared; Woods, Amber; Fu, Tihui; He, Qiuming; Nielsen, Michael C; Hasan, Farah; Roszik, Jason; Xiao, Zhilan; Vianden, Christina; Khong, Hiep; Singh, Manisha; Sharma, Meenu; Faak, Faisal; Moore, Derek; Dai, Zhimin; Anthony, Scott M; Schluns, Kimberly S; Sharma, Padmanee; Engelhard, Victor H; Overwijk, Willem W.
Afiliação
  • Hailemichael Y; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Woods A; Department of Microbiology, Immunology, and Cancer Biology, Carter Immunology Center, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
  • Fu T; Department of Genitourinary Medical Oncology/Immunology and.
  • He Q; Department of Genitourinary Medical Oncology/Immunology and.
  • Nielsen MC; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Hasan F; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Roszik J; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Xiao Z; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Vianden C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Khong H; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Singh M; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Sharma M; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Faak F; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Moore D; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Dai Z; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Anthony SM; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Schluns KS; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Sharma P; The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas, USA.
  • Engelhard VH; Department of Genitourinary Medical Oncology/Immunology and.
  • Overwijk WW; Department of Microbiology, Immunology, and Cancer Biology, Carter Immunology Center, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
J Clin Invest ; 128(4): 1338-1354, 2018 04 02.
Article em En | MEDLINE | ID: mdl-29480817
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Peptídeos / Vacinas Anticâncer / Antígeno gp100 de Melanoma / Antígeno B7-H1 / Antígeno CTLA-4 / Pontos de Checagem do Ciclo Celular / Melanoma / Neoplasias Experimentais Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Peptídeos / Vacinas Anticâncer / Antígeno gp100 de Melanoma / Antígeno B7-H1 / Antígeno CTLA-4 / Pontos de Checagem do Ciclo Celular / Melanoma / Neoplasias Experimentais Idioma: En Ano de publicação: 2018 Tipo de documento: Article